+477.7%
HUT vs MRNA
+156.2%
+321.4%
-65.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +6.0% | -4.8% | +10.8% | +6.4% |
| 7D | -6.3% | -20.9% | +14.5% | -4.4% |
| 30D | -16.1% | -13.3% | -2.8% | -15.3% |
| 3M | -29.2% | +212.6% | -241.8% | -41.4% |
| 6M | -40.6% | +309.0% | -349.6% | -55.6% |
| YTD | +24.5% | +567.3% | -542.8% | -18.7% |
| 1Y | +47.9% | +689.7% | -641.8% | -7.1% |
| All | +477.7% | +156.2% | +321.4% | +316.7% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling